fosinopril has been researched along with losartan in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, TC; Huang, WC | 1 |
| Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J | 1 |
| Liang, X; Su, M; Xie, X; Yu, G; Zhao, S | 1 |
| Erem, C; Kavgaci, H; Onder Ersoz, H; Ozdemir, F; Sahin, A | 1 |
| Liang, X; Sun, M; Xie, X; Yang, T; Yu, G; Zhao, S | 1 |
| Liang, XQ; Yu, GL; Zheng, JQ | 1 |
| He, BX; Liang, XQ; Yu, GL | 1 |
| Huang, YH; Shen, W; Wang, HT; Wang, Y; Zhang, H; Zhu, QZ | 1 |
| Abdel-Salam, OM; Arbid, MS; el-Batran, SA; el-Shenawy, SM; Nofal, SM | 1 |
| Cheng, XS; He, JG; Li, L; Li, YH; Liu, GZ; Ruan, YM; Wu, ZJ | 1 |
| Abdallah, HM; El-Batran, SA; El-Demerdash, E; Salam, OM; Shaffie, NM | 1 |
| Nayak, V; Patil, PA | 1 |
| Ao, X; Tang, R; Tang, TF; Zhou, QL; Zhu, LL | 1 |
| Deng, JL; Hou, YB; Li, J; Wang, H; Yue, J | 1 |
| Liu, Z; Pouranan, V; Tang, R; Xiao, Z; Zhou, Q | 1 |
| Ao, X; Peng, WS; Tang, R; Tang, TF; Veeraragoo, P; Zhou, QL | 1 |
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
3 review(s) available for fosinopril and losartan
| Article | Year |
|---|---|
Prostaglandin E1 for preventing the progression of diabetic kidney disease.
Topics: Albuminuria; Alprostadil; Diabetic Nephropathies; Disease Progression; Drugs, Chinese Herbal; Fosinopril; Humans; Losartan; Proteinuria; Randomized Controlled Trials as Topic; Vasodilator Agents | 2010 |
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fosinopril and losartan
| Article | Year |
|---|---|
The effects of losartan and fosinopril in hypertensive type 2 diabetic patients.
Topics: Adult; Alanine Transaminase; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspartate Aminotransferases; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Dose-Response Relationship, Drug; Electrolytes; Female; Fosinopril; Humans; Hypertension; Hypoglycemic Agents; Insulin; Lipids; Losartan; Male; Middle Aged; Time Factors | 2002 |
17 other study(ies) available for fosinopril and losartan
| Article | Year |
|---|---|
Role of angiotensin II in hyperinsulinemia-induced hypertension in rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Chronic Disease; Fosinopril; Hyperinsulinism; Hypertension; Insulin; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley | 1998 |
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Drug Administration Schedule; Fosinopril; Hydralazine; Hypertension; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Mice; Mice, Transgenic; Oxidation-Reduction; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 1999 |
Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; China; Disease Models, Animal; Fosinopril; Heart Ventricles; Hypertrophy, Left Ventricular; Losartan; Models, Cardiovascular; Myocardium; Random Allocation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1 | 2001 |
Apoptosis, myocardial fibrosis and angiotensin II in the left ventricle of hypertensive rats treated with fosinopril or losartan.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Blood Pressure; Fibrosis; Fosinopril; Hypertension; Hypertrophy, Left Ventricular; Losartan; Myocardium; Rats; Rats, Inbred SHR | 2002 |
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Cardiotonic Agents; Female; Fosinopril; Hypertension; Losartan; Male; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred SHR; Ventricular Remodeling | 2001 |
[Effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II and cardiac remolding in hypertensive rats].
Topics: Angiotensin II; Animals; Antihypertensive Agents; Fibrosis; Fosinopril; Hypertension; Losartan; Male; Myocardium; Random Allocation; Rats; Rats, Inbred SHR; Ventricular Remodeling | 2001 |
[Combination therapy with losartan and fosinopril for early diabetic nephropathy].
Topics: Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Fosinopril; Humans; Losartan | 2003 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Therapy, Combination; Egypt; Fosinopril; Gliclazide; Hyperlipidemias; Hypolipidemic Agents; Lipids; Losartan; Male; Piperidines; Rats; Rats, Sprague-Dawley; Triglycerides | 2004 |
[Changes of collagen expression of pulmonary arteries and heart ventricles and intervention of fosinopril and losartan in rats with heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Female; Fosinopril; Heart Failure; Heart Ventricles; Losartan; Pulmonary Artery; Rats; Rats, Sprague-Dawley | 2004 |
Inhibition of the renin-angiotensin system attenuates the development of liver fibrosis and oxidative stress in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Carbon Tetrachloride; Disease Models, Animal; Dose-Response Relationship, Drug; Fosinopril; Glutathione; Hydroxyproline; Lipid Peroxidation; Lisinopril; Liver; Liver Cirrhosis; Liver Function Tests; Losartan; Male; Oxidative Stress; Rats; Renin-Angiotensin System | 2008 |
Antidepressant activity of fosinopril, ramipril and losartan, but not of lisinopril in depressive paradigms of albino rats and mice.
Topics: Amitriptyline; Analysis of Variance; Animals; Antidepressive Agents; Antihypertensive Agents; Fosinopril; Lisinopril; Long-Term Synaptic Depression; Losartan; Male; Mice; Motor Activity; Ramipril; Rats; Rats, Wistar | 2008 |
[Effects of fosinopril and losartan on the expression of Toll- like receptor 4 in renal tubular epithelia cells].
Topics: Animals; Cell Line; Epithelial Cells; Fosinopril; Hypertension; Kidney Diseases; Kidney Tubules; Losartan; Rats; RNA Interference; RNA, Messenger; Toll-Like Receptor 4 | 2008 |
Effects of fosinopril and losartan on renal Klotho expression and oxidative stress in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Fosinopril; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Losartan; Male; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger | 2011 |
Fosinopril and losartan regulate klotho gene and nicotinamide adenine dinucleotide phosphate oxidase expression in kidneys of spontaneously hypertensive rats.
Topics: Animals; Disease Progression; Fosinopril; Gene Expression Regulation, Enzymologic; Glucuronidase; Hypertension; Kidney; Klotho Proteins; Losartan; Male; NADPH Oxidases; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger | 2011 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |